A nano-sized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma

  • Meser M. Ali
  • , Mohammed P.I. Bhuiyan
  • , Branislava Janic
  • , Nadimpalli R.S. Varma
  • , Tom Mikkelsen
  • , James R. Ewing
  • , Robert A. Knight
  • , Mark D. Pagel
  • , Ali S. Arbab

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: The authors have investigated the usefulness of in vivo chemical exchange saturation transfer MRI for detecting gliomas using a dual-modality imaging contrast agent. Materials & methods: A paramagnetic chemical exchange saturation transfer MRI contrast agent, Eu-1,4,7,10- tetraazacclododecane-1,4,7,10-tetraacetic acid-Gly4 and a fluorescent agent, DyLight® 680, were conjugated to a generation 5 polyamidoamine dendrimer to create the dual-modality, nano-sized imaging contrast agent. Results: The agent was detected with in vivo chemical exchange saturation transfer MRI in an U87 glioma model. These results were validated using in vivo and ex vivo fluorescence imaging. Conclusion: This study demonstrated the merits of using a nano-sized imaging contrast agent for detecting gliomas and using a dual-modality agent for detecting gliomas at different spatial scales. Original submitted 9 January 2012; Revised submitted 18 April 2012; Published online 14 August 201.

Original languageEnglish (US)
Pages (from-to)1827-1837
Number of pages11
JournalNanomedicine
Volume7
Issue number12
DOIs
StatePublished - Dec 2012

Keywords

  • MRI
  • brain tumor
  • contrast agent
  • dendrimer
  • pharmacokinetic

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • General Materials Science
  • Development

Fingerprint

Dive into the research topics of 'A nano-sized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma'. Together they form a unique fingerprint.

Cite this